Search

Displaying results 3191 - 3200 of 4300 in total
  1. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  2. Drug

    AGA2115

    go.drugbank.com/drugs/DB17840
    Investigational

    Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]

  3. Drug

    Agatolimod

    go.drugbank.com/drugs/DB15018
    Investigational

    Agatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).

  4. Drug

    XT-150

    go.drugbank.com/drugs/DB21756
    Investigational

    [L52125] It is being developed by Xalud Therapeutics.

  5. Drug

    Pranlukast

    go.drugbank.com/drugs/DB01411
    Investigational

    It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

  6. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform.

  7. Drug

    Doramectin

    go.drugbank.com/drugs/DB11400
    ExperimentalVet approved

    Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites

  8. Drug

    Boron

    go.drugbank.com/drugs/DB11203
    ApprovedInvestigational

    Natural boron exists in 2 stable isotopes however pure boron is hard to prepare due to contamination by different elements.

  9. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    [A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.

  10. Drug

    Candesartan cilexetil

    go.drugbank.com/drugs/DB00796
    ApprovedInvestigational

    Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents